| Doxorubicin (Adriamycin) |
ARA |
Curated lncRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
ARA |
Curated lncRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
C10orf101 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000100181.17 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000131484.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000135253.9 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000146666.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000152487.6 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000157306.10 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000175147.7 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000175773.8 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000177406.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000178803.6 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000179219.5 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000179743.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000179935.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000180846.4 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000180846.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000181097.5 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000182021.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000182165.13 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000182376.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000182648.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000183242.7 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000184068.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000184274.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000184274.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000184274.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000184324.11 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000184324.11 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000185186.4 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000186056.5 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000186594.8 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000187156.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000196951.6 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000197463.8 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000197463.8 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000197989.9 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000203288.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000203307.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000203496.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000203808.6 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000203875.6 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000203999.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204044.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204044.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000204362.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204362.5 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204625.6 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204758.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000204758.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204758.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204792.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204860.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000204929.7 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000205890.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000206176.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000206176.5 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000206176.5 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000206195.6 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000206417.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000206417.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000206567.5 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000211683.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000211683.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000212163.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000212552.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000213468.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000213963.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000213971.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000214347.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000214770.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000214803.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000215022.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000215039.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000215304.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000215394.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000215417.6 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000215498.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000215863.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000215869.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000216863.5 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223356.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223390.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223393.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223477.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223528.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223528.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223571.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000223571.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223576.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223714.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223734.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223759.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223774.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223779.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223779.4 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223812.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223834.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223842.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000223935.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224020.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000224031.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224034.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224043.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224081.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224116.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224165.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224269.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224272.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224394.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224429.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224505.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224635.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224652.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224687.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224698.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224698.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224733.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224805.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224843.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224844.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224885.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224973.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224977.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000224992.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225032.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000225037.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225037.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225075.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225087.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225113.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225113.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225113.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225177.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225177.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225210.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225218.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000225234.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225269.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225311.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225439.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225518.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225541.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225675.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225675.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225684.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225767.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000225778.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000225778.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225889.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225937.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225956.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225975.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000225975.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226026.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226067.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226091.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226115.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000226245.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000226263.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226330.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226352.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226367.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226377.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226380.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226380.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226380.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226381.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226386.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000226419.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226445.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226453.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226465.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226578.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226609.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226637.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226649.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226679.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226699.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226754.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226756.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226800.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226803.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226812.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226816.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226835.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226876.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226883.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226889.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000226920.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000226950.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000227060.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227071.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227214.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227279.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227285.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227308.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227375.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000227375.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227496.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227543.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227588.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227589.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227591.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227603.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227634.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227637.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227646.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227678.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227704.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227740.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227844.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227895.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227895.4 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227896.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227906.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227925.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000227963.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228010.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228065.6 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228079.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228084.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000228109.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228109.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228115.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228153.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228201.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228242.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228251.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228293.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228294.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228315.7 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228323.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000228353.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228395.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228404.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228470.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228496.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228630.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228643.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228643.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228649.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228649.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228792.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228794.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228817.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228939.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228989.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000228989.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229036.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229043.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229111.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229111.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000229160.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229191.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229227.4 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229267.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229331.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229348.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229404.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229558.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229591.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229656.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229692.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229697.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229776.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229832.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229839.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229852.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229852.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229891.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229931.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229931.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229964.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229989.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000229996.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230010.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230021.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230021.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230090.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230153.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230289.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230310.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230479.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230506.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230550.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230552.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230590.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230606.6 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230615.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230695.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230736.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230751.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230773.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230850.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230857.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230876.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230880.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230914.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230925.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230937.5 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000230940.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231050.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231073.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231106.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231107.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231128.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231134.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231249.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231290.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231294.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231298.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231305.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231327.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231329.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231365.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231393.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000231465.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231473.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231505.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231528.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231551.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231595.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231646.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231646.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231691.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231709.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231713.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231734.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231742.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231794.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000231840.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231851.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231856.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231889.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231889.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231908.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231927.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000231944.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231966.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231971.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000231999.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232019.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232028.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232044.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232057.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232093.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232194.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232300.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232324.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232354.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232386.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232406.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232406.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232445.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232445.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232445.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232448.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232455.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232490.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232504.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232533.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232593.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232611.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232642.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232656.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000232684.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232759.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232807.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000232876.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000232876.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232891.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232909.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232931.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000232936.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232949.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000232956.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233056.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233077.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233183.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233244.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233250.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233296.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000233296.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233430.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233430.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233496.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233509.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233515.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233532.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233547.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233547.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233611.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233621.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233621.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233776.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233806.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233818.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233864.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233864.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233885.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233930.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000233937.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234006.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234019.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234062.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234084.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234155.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234156.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234160.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234160.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234160.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234171.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234199.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234215.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234235.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234380.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234476.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234477.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234584.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234661.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234665.4 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234690.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234694.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000234694.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234741.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234753.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234753.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234753.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234902.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234917.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000234948.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235079.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235151.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235159.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235189.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235214.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235257.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235398.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235427.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235461.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235499.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235590.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235593.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235724.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235781.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235802.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000235823.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235848.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235848.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235884.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235890.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235908.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235919.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235954.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235958.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000235999.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236051.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236064.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236066.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236144.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236199.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236204.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236204.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236206.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236244.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236308.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000236352.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236358.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236383.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236393.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236423.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236438.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236467.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236540.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236558.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236558.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236617.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236618.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236643.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236651.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236740.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236751.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236751.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236780.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236799.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236842.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236869.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236871.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236889.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236914.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236936.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000236943.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237021.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237021.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237234.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237328.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000237336.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237361.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237424.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237476.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237481.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237505.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237520.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237525.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237595.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237685.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237689.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000237705.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237756.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237768.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237803.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237805.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000237805.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237899.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237903.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237934.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000237937.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237940.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237943.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237943.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000237945.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000237976.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000238005.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238005.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238039.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238042.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238122.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238160.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238197.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238279.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238287.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000238290.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000239335.4 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000239462.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000239498.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000239608.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000239641.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000239677.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000240005.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000240050.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000240086.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000240401.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000240476.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000240541.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000240758.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000240922.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241219.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241220.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241288.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241449.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241505.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241520.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241570.4 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241666.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000241954.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241985.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000241990.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000242125.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000242282.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000242290.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000242375.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000242540.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000243069.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000243350.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000243797.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000243849.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000243960.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000243967.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244055.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000244198.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244203.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000244260.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244286.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244306.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244349.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244380.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244459.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244479.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244558.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244586.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244676.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244676.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000244968.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000245059.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000245060.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000245112.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000245213.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000245281.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000245311.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000245651.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000245768.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000246067.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000246263.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000246528.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000246582.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000246790.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000246792.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247092.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247092.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247131.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247137.4 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247240.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247240.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247363.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247516.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247828.3 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247877.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000247925.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248100.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248100.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248125.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248175.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248240.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248245.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248275.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248367.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248388.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248416.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248468.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248571.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248664.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248664.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248668.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000248758.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000248774.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248774.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248787.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248884.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248896.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000248968.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000248996.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249028.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249167.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249207.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249234.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249252.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000249295.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249345.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249378.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249379.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249451.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249487.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000249584.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249592.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249595.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249604.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249635.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249637.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249637.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249684.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000249685.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249740.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249870.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249898.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000249942.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250027.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250041.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250049.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250159.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250167.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250192.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250240.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250260.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250286.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250366.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250366.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250404.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250409.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250451.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250511.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250548.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250551.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250602.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250608.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250635.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250659.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250659.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250714.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250786.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250802.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000250988.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251136.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251143.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251144.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251148.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251164.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251314.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251323.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000251379.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251414.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251497.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251523.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251604.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000251666.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253111.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253116.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253125.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253210.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253302.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253307.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253311.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253347.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253374.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000253477.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253526.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253552.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253559.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253582.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253596.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253616.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253636.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253641.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253666.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253666.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253696.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253708.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000253802.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253859.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000253875.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253893.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000253917.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253947.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253961.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000253978.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254057.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254142.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254144.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254144.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254154.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254207.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254246.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254267.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254333.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254353.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254363.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254409.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254427.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254427.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254554.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254560.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254592.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000254615.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254688.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254691.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000254691.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254718.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254733.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254739.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254812.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254847.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254859.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254859.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000254910.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255031.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255052.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000255082.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255089.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255090.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255145.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255148.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255186.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255234.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255236.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255236.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255250.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255310.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255311.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255320.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255410.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255449.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255503.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255521.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255571.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255621.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255693.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255717.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255741.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000255741.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255808.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000255968.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256031.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256083.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256084.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256092.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256234.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256268.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256278.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256427.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256603.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256609.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256705.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000256802.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257038.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257058.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257095.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257151.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000257183.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257264.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257271.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257279.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257285.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257303.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257433.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257475.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257497.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257568.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000257596.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257605.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257636.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257681.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000257696.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257732.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257808.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000257808.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257910.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000257925.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258017.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258077.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258082.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258099.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258101.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258136.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258181.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258181.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258240.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258303.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258334.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258344.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258400.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258413.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258425.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258454.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000258457.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258458.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258486.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258525.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258534.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258537.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258561.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258693.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258731.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258754.3 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258777.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258821.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258825.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258825.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258857.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258860.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258904.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258920.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258920.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258929.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000258976.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259055.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000259065.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259065.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259135.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000259158.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259187.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259201.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259209.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259238.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259250.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000259296.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259342.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259376.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259416.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259432.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259439.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259453.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259473.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259514.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259523.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259527.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259553.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259583.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259604.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259623.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259623.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259635.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259640.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259654.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259682.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259705.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259713.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259727.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259736.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259758.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259762.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259767.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259768.3 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259774.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259804.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000259834.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259863.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259883.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259883.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259894.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000259901.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259953.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259954.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259959.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259967.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259969.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259986.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000259994.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260017.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000260017.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260022.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260022.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000260030.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260059.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260060.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260081.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260136.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260141.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260141.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260156.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000260167.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260167.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260176.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260190.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260190.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260196.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260248.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260260.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260261.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260269.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260278.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000260281.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260285.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260296.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000260296.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260328.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260328.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260331.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260352.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260369.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260369.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260423.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000260439.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260440.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260447.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260447.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260448.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260507.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260515.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260572.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260579.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260583.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260591.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260614.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260619.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260641.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260645.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260647.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260648.2 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260664.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260708.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260743.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260743.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260803.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260814.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260823.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260831.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260841.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260855.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260874.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260910.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260920.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260924.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260927.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260938.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260947.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260954.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260954.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000260973.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000260986.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000260986.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261003.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000261005.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261018.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261019.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261040.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261094.2 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261096.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261122.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261141.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261159.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261167.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261186.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261187.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261188.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261204.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261273.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261280.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261288.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261291.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261318.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000261329.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261384.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261392.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261428.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000261428.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261431.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261433.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261442.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261455.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261455.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261468.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261476.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000261512.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261521.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261523.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261526.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261533.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261589.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261600.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261610.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261613.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261663.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261669.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261697.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261770.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261773.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261798.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261823.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261839.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000261840.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261886.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000261925.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000261971.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262172.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262222.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262319.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262362.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262410.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262410.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262410.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262772.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262810.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262837.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262879.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000262951.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263013.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263069.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263080.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263338.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263350.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263350.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263350.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263388.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263393.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263412.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263470.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263499.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263567.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263603.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263624.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263627.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263657.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000263745.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263753.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263766.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000263938.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264043.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264188.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264222.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264247.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264290.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264339.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264365.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264456.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264513.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264548.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264577.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264608.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264635.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264647.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264785.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264808.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000264932.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000265094.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000265185.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000265242.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000265342.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000265519.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000265666.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000265728.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000265787.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266040.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266088.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266236.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000266278.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266290.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266397.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266401.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266402.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266402.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266402.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266456.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266579.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266579.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266654.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266677.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000266677.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266801.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266904.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266912.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266912.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266926.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266969.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000266976.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000266983.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267009.2 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267053.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267080.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267096.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267100.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267108.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267112.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267121.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267123.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267130.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267147.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267150.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267150.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267161.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267161.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267161.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267167.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267194.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267197.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267199.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267201.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267207.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267232.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267255.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267255.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267263.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267265.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267272.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267273.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267298.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267302.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267316.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267317.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267321.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267321.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267334.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267374.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267375.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267375.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267390.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267416.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267440.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267480.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267491.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267498.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267504.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267543.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267551.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267551.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267567.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267568.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267605.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267606.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267644.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267655.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267666.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267667.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267672.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267696.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267701.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267729.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267745.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267765.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267783.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000267783.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267798.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267874.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267924.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000267940.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268015.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268157.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268186.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268205.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268205.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268289.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268307.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268340.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000268362.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268516.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268530.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268530.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268543.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268543.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268613.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268836.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268842.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268912.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000268945.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000269038.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269044.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269066.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269082.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269102.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269161.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269194.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000269235.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269246.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269397.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269473.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269473.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269600.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269680.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269720.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269873.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269893.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269895.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269910.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269918.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269923.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269938.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269940.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269947.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269947.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269951.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000269996.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000269997.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270006.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270041.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270048.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000270049.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270050.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270066.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270068.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270074.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000270084.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270109.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000270110.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270115.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270116.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270117.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000270137.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270159.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000270159.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270164.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270168.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270170.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270189.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270190.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270223.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270237.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000270246.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270482.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000270589.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270760.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000270828.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000270988.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271119.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271127.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271133.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271344.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271367.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000271382.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271384.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271427.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271576.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271659.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271715.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271716.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271717.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000271752.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271755.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271757.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271782.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271782.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271782.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271821.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271830.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271833.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271833.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271835.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271849.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271857.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271869.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000271871.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271912.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271916.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271948.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000271966.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000271993.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271996.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000271997.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000271998.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272002.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272005.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272023.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272023.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272070.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272077.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272077.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272097.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272141.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272183.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272205.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272205.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272221.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272221.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272248.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272273.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272301.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272301.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272308.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272312.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272320.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272327.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272328.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272365.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272365.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272366.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272373.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272374.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272389.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272416.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272416.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272426.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272432.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272452.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272452.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272452.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272452.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272457.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272462.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272462.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272463.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272465.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272516.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272524.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272524.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272525.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272529.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272556.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272558.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272562.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272567.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272567.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272576.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272627.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272630.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272639.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272657.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272660.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272677.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272677.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272682.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272692.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272699.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272699.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272702.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272707.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272710.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272717.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272717.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272734.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272734.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272754.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272755.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272777.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272777.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272782.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272787.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272787.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272789.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272795.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272808.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272810.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000272824.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272827.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272828.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272829.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272856.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272861.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272872.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272902.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272904.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272931.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272940.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272942.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272966.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272977.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272983.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000272995.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000273000.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273001.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000273004.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273004.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273009.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273056.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273065.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273073.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273073.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000273077.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273081.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273084.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273091.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000273097.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273097.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273104.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273117.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273129.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273142.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273156.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000273165.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273175.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273179.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273186.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273186.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273188.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273190.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273203.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273237.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273257.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273270.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273281.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273290.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273293.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273295.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273297.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273306.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273335.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273338.1 |
Predicted lncRNA |
Colon adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273355.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273373.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273373.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273374.1 |
Predicted lncRNA |
Sarcoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273375.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273402.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273428.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000273443.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
ENSG00000273447.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Doxorubicin (Adriamycin) |
ENSG00000273473.1 |
Predicted lncRNA |
Lymphoid neoplasm diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
FENDRR |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
FOXC2-AS1 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
H19 |
Curated lncRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
H19 |
Curated lncRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
H19 |
Curated lncRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-12 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-13 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-14 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-mir-15 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-17 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-19 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-25 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-26 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-mir-27 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-41 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-43 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-5 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-50 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-51 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-57 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-58 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-64 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-65 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-71 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-miR-72 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novel-mir-8 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
hsa-novelmiR-35 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
let-7a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
let-7a |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
let-7a |
Curated miRNA |
melanoma |
|
| Doxorubicin (Adriamycin) |
let-7a |
Curated miRNA |
squamous carcinoma |
|
| Doxorubicin (Adriamycin) |
let-7b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
let-7c |
Curated miRNA |
The Ewing sarcoma/primitive neuroectodermal tumor |
|
| Doxorubicin (Adriamycin) |
let-7d |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
let-7e |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
let-7e |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
let-7e |
Curated miRNA |
ovarian cancer |
|
| Doxorubicin (Adriamycin) |
let-7e* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
let-7f |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
let-7f |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
let-7g |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
let-7g |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
let-7i |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
LINC00944 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
LINC01116 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-ADCY9-1 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-ANO9-1 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-BCAN-1:1 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-CA5A-4 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-COL6A1-1 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-NBPF16-3 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-PDGFRB |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-PHLDA3 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-PRSS21 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-RP11-597K23.2.1-2 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-RPS24-3 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
lnc-RXRG-1 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
Lnc-VLDLR |
Curated lncRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
lnc-ZNF706-1 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
MGC12916 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-1 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-1 |
Curated miRNA |
lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-100 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-100 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-100 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-101 |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-101 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-101 |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-101* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-103 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-103 |
Curated miRNA |
gastric carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-106a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-106a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-106a |
Curated miRNA |
ovarian cancer |
|
| Doxorubicin (Adriamycin) |
miR-106b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-107 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-107 |
Curated miRNA |
gastric carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-108a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-10a |
Curated miRNA |
acute myeloid leukemia |
|
| Doxorubicin (Adriamycin) |
miR-10a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-10a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-10a* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-10b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-122 |
Curated miRNA |
cutaneous T-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
miR-122 |
Curated miRNA |
hepatocarcinoma |
|
| Doxorubicin (Adriamycin) |
miR-122 |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-1224 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-1226 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1226* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1228* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1229 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-1233 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1234 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1236 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-1238 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-124 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-124 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-124 |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-1246 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-125-1 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-1253 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1254 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-1255a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-1256 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-125a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-125a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-125a |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-125b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-125b |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-125b |
Curated miRNA |
ewing sarcoma |
|
| Doxorubicin (Adriamycin) |
miR-125b |
Curated miRNA |
pediatric acute promyelocytic leukemia |
|
| Doxorubicin (Adriamycin) |
miR-125b-1 |
Curated miRNA |
neuroblastoma |
|
| Doxorubicin (Adriamycin) |
miR-125b-1* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-126 |
Curated miRNA |
non-small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-126 |
Curated miRNA |
ovarian cancer |
|
| Doxorubicin (Adriamycin) |
miR-1265 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1269 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-1269b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-127 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-127 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-127 |
Curated miRNA |
glioma |
|
| Doxorubicin (Adriamycin) |
miR-127 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-127 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-1273d |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-1273g |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-1277 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-128 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-128 |
Curated miRNA |
breast tumor-initiating cells |
|
| Doxorubicin (Adriamycin) |
miR-128-2 |
Curated miRNA |
non-small-cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-128a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-128b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-129 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-129 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-129 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1291 |
Curated miRNA |
- |
|
| Doxorubicin (Adriamycin) |
miR-1291 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-1291 |
Curated miRNA |
pancreatic carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-1293 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-1299 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-130a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-130b* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-132 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-132 |
Curated miRNA |
ovarian cancer |
|
| Doxorubicin (Adriamycin) |
miR-133a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-133a |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-133b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-133b |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-134 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-134 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-135 |
Curated miRNA |
cervical carcinoma, colon cancer |
|
| Doxorubicin (Adriamycin) |
miR-135a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-135a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-135b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-135b |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-135b |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-137 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-137 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-137 |
Curated miRNA |
neuroblastoma |
|
| Doxorubicin (Adriamycin) |
miR-138 |
Curated miRNA |
cervical carcinoma, colon cancer |
|
| Doxorubicin (Adriamycin) |
miR-138 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-138-1* |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-139 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-139 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-140 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-140 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-141 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-141 |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-141* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-142 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-142 |
Curated miRNA |
ovarian cancer |
|
| Doxorubicin (Adriamycin) |
miR-143 |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-143 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-143* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-145 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-145 |
Curated miRNA |
esophageal cancer |
|
| Doxorubicin (Adriamycin) |
miR-145 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-145 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-146a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-146a |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-146a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-146b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-146b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-148a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-148a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-148a |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-149 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-149 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-150 |
Curated miRNA |
neuroblastoma |
|
| Doxorubicin (Adriamycin) |
miR-151 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-152 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-153 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-1538 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1539 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-154* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-155 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-155 |
Curated miRNA |
colorectal cancer |
|
| Doxorubicin (Adriamycin) |
miR-155 |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-155 |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-15a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-15a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-15a* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-15a* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-15b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-15b* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-16 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-16 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-16 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-16 |
Curated miRNA |
lung adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
miR-17 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-17 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-17 |
Curated miRNA |
synovial sarcoma |
|
| Doxorubicin (Adriamycin) |
miR-17* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-17-92 |
Curated miRNA |
mantle cell lymphoma |
|
| Doxorubicin (Adriamycin) |
miR-181a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-181a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-181a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-181a |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-181a |
Curated miRNA |
ovarian cancer |
|
| Doxorubicin (Adriamycin) |
miR-181a* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-181b |
Curated miRNA |
acute myeloid leukemia |
|
| Doxorubicin (Adriamycin) |
miR-181b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-181b |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-181b |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-181c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-181d |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-181d |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-182 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-182 |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-182* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-183 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-183 |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-183 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-184 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-185 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-185 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-185 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-186 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-186* |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-187 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-187 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-187 |
Curated miRNA |
peripheral T-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
miR-188 |
Curated miRNA |
neuroblastoma |
|
| Doxorubicin (Adriamycin) |
miR-18a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-18b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-18b |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-190 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-190 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-1908 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-191 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-191* |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-1911 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1911* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1915 |
Curated miRNA |
colorectal carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-1915 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-1915 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-1915* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-192 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-192* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-193a |
Curated miRNA |
bladder cancer |
|
| Doxorubicin (Adriamycin) |
miR-193a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-193b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-193b |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-193b* |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-194 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-194 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-195 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-195 |
Curated miRNA |
colon cancer |
|
| Doxorubicin (Adriamycin) |
miR-195 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-196a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-196a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-196b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-197 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-199a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-199a |
Curated miRNA |
colorectal cancer |
|
| Doxorubicin (Adriamycin) |
miR-199a |
Curated miRNA |
diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
miR-199a |
Curated miRNA |
hepatocarcinoma |
|
| Doxorubicin (Adriamycin) |
miR-199a |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-199a |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-199a |
Curated miRNA |
ovarian cancer |
|
| Doxorubicin (Adriamycin) |
miR-199a* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-199b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-19a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-19a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-19b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-19b |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-19b-1* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-200a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-200a* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-200b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-200b |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-200b |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-200c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-200c |
Curated miRNA |
esophageal cancer |
|
| Doxorubicin (Adriamycin) |
miR-200c |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-202 |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-202* |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-203 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-203 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-203 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-204 |
Curated miRNA |
neuroblastoma |
|
| Doxorubicin (Adriamycin) |
miR-205 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-205 |
Curated miRNA |
melanoma |
|
| Doxorubicin (Adriamycin) |
miR-206 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-20a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-20a |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-20a* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-20b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-20b |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-20b* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-21 |
Curated miRNA |
bladder cancer |
|
| Doxorubicin (Adriamycin) |
miR-21 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-21 |
Curated miRNA |
chronic myeloid leukemia |
|
| Doxorubicin (Adriamycin) |
miR-21 |
Curated miRNA |
diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
miR-21 |
Curated miRNA |
esophageal cancer |
|
| Doxorubicin (Adriamycin) |
miR-21 |
Curated miRNA |
glioblastoma |
|
| Doxorubicin (Adriamycin) |
miR-21 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-21* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-210 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-210 |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-210 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-210 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-211 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-2116 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-212 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-214 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-214 |
Curated miRNA |
esophageal squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-214 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-214* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-214* |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-215 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-215 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-216a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-216a |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-216b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-217 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-218 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-218 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-219 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-22 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-22 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-22 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-22 |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-220 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-221 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-221 |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-221 |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-222 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-223 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-223 |
Curated miRNA |
esophageal adenocarcinoma |
|
| Doxorubicin (Adriamycin) |
miR-223 |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-224 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-224 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-2277 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-23a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-23a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-23b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-23b* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-25 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-25* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-2682 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-26a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-26a-MM1 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-26b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-26b |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-27a |
Curated miRNA |
bladder cancer |
|
| Doxorubicin (Adriamycin) |
miR-27a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-27a |
Curated miRNA |
cancer |
|
| Doxorubicin (Adriamycin) |
miR-27a |
Curated miRNA |
esophageal squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-27a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-27a |
Curated miRNA |
leukaemia |
|
| Doxorubicin (Adriamycin) |
miR-27b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-27b |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-27b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-27b |
Curated miRNA |
kidney cancer |
|
| Doxorubicin (Adriamycin) |
miR-27b |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-28 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-28 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-296 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-296 |
Curated miRNA |
esophageal squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-296 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-297 |
Curated miRNA |
colorectal cancer |
|
| Doxorubicin (Adriamycin) |
miR-297 |
Curated miRNA |
colorectal carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-297 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-298 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-299 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-299 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-299 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-29a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-29a* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-29b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-29b-1 |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-29b-2* |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-29c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-300 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-301 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-301a |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-301b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-302a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-302b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-302c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-302c* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-30a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-30a* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-30b |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-30b |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-30b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-30b* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-30c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-30c |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-30d |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-30d* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-30e |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-30e |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-30e* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-31 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-31 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-31* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-3117 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-3117 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-3131 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-3149 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-3162 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-3183 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-3186 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-32 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-32 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-320 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-320a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-320d |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-323 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-323 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-324 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-324 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-326 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-326 |
Curated miRNA |
hepatocellular carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-326 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-328 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-329 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-330 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-331 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-331 |
Curated miRNA |
leukaemia |
|
| Doxorubicin (Adriamycin) |
miR-335 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-338 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-338 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-338 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-338 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-339 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-33a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-33a |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-33a* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-33b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-34 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-342 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-342 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-342 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-345 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-34a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-34a |
Curated miRNA |
ewing sarcoma |
|
| Doxorubicin (Adriamycin) |
miR-34a |
Curated miRNA |
triple negative breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-34b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-34c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-34c |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-34c |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-361 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-361 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-362 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-362 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-3622a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-3654 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-365a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-365b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-3660 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-367 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-367 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-3674 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-3679 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-368 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-3681 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-3681* |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-3687 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-369 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-369 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-370 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-371 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-372 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-373 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-373* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-374 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-374a* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-375 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-375 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-376a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-376a |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-376a |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-376b |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-376c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-376c |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-376c |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-377 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-378 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-378a |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-379 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-379 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-379 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-380 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-380 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-381 |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-382 |
Curated miRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
miR-382 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-383* |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-3910 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-409 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-409 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-409 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-409 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-410 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-410 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-411 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-411 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-412 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-421 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-422a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-424 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-424 |
Curated miRNA |
cancer |
|
| Doxorubicin (Adriamycin) |
miR-424 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-424 |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-425 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-425 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-4258 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-4284 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-4285 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-429 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-429 |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-431 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-4311 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-432 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-432 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-433 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-4426 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-4427 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-4430 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-4448 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-4454 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-448 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-4485 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-4488 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-450 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-4501 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-4508 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-450a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-451 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-451 |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-451a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-452 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-453 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-454 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-455 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-455 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-455 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-4687 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-4701 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-4728 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-4763 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-483 |
Curated miRNA |
esophageal squamous cell carcinoma |
|
| Doxorubicin (Adriamycin) |
miR-484 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-485 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-485 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-485 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-485 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-485 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-486 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-486 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-486 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-487a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-487b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-487b |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-487b |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-487b |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-488 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-489 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-489 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-491 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-493 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-494 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-494 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-494 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-495 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-495 |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-495 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-495 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-496 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-497 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-497 |
Curated miRNA |
diffuse large B-cell lymphoma |
|
| Doxorubicin (Adriamycin) |
miR-499 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-500 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-500a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-500b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-501 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-501-5P |
Curated miRNA |
neuroblastoma |
|
| Doxorubicin (Adriamycin) |
miR-502 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-503 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-503 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-503 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-505 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-508 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-508 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-509 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-509 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-5096 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-513a |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-513c |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-514 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-514 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-517a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-517b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-517c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-519 |
Curated miRNA |
neuroblastoma |
|
| Doxorubicin (Adriamycin) |
miR-519b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-519b |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-520 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-520a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-520b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-520c |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-520c |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-520d |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-520f |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-520g |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-520h |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-520h |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-522 |
Curated miRNA |
colon cancer |
|
| Doxorubicin (Adriamycin) |
miR-523 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-526a |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-526b* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-532 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-532 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-539 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-541* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-542 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-542 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-542 |
Curated miRNA |
triple negative breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-545 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-548a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-548h |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-550 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-551b |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-551b |
Curated miRNA |
lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-555 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-557 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-560 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-563 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-563 |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-565 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-568 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-569 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-571 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-574 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-576 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-577 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-577 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-578 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-582 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-584 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-584 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-584 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-586 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-587 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-587 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-588 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-589* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-590 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-591 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-592 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-593 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-593* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-594 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-601 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-605 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-606 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-606 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-612 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-613 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-615 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-615 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-620 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-621 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-625 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-628 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-629 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-630 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-633 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-634 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-634 |
Curated miRNA |
ovarian cancer |
|
| Doxorubicin (Adriamycin) |
miR-635 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-637 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-639 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-639 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-642a |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-642a |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-643 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-649 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-651 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-652 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-654 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-654 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-655 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-660 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-662 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-664* |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-675 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-680 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-7 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-7 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-7 |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-7-1* |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-708 |
Curated miRNA |
ewing sarcoma |
|
| Doxorubicin (Adriamycin) |
miR-708 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-720 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-758 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-760 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-760 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-765 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-766 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-767 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-769 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-769 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-769 |
Curated miRNA |
neuroblastoma |
|
| Doxorubicin (Adriamycin) |
miR-802 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-876 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-876 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
miR-877 |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-877 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-881* |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-885 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-886 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-886 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-888 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-889 |
Curated miRNA |
chronic myelogenous leukemia |
|
| Doxorubicin (Adriamycin) |
miR-891b |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-892b |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-9 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-92 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-920 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-922 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-924 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-92a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-92b |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-93 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-93 |
Curated miRNA |
The Ewing sarcoma/primitive neuroectodermal tumor |
|
| Doxorubicin (Adriamycin) |
miR-933 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-934 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-935 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-944 |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-96 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-96 |
Curated miRNA |
ehrlich ascites tumor |
|
| Doxorubicin (Adriamycin) |
miR-98 |
Curated miRNA |
leukemia |
|
| Doxorubicin (Adriamycin) |
miR-98 |
Curated miRNA |
liver cancer |
|
| Doxorubicin (Adriamycin) |
miR-99a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-99b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
miR-99b |
Curated miRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
miR-99b |
Curated miRNA |
small cell lung cancer |
|
| Doxorubicin (Adriamycin) |
miR-99b* |
Curated miRNA |
hepatocellular cancer |
|
| Doxorubicin (Adriamycin) |
miR-Plus-A1031 |
Curated miRNA |
diffuse large B cell lymphoma (DLBCL) |
|
| Doxorubicin (Adriamycin) |
MIR503HG |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
mmu-miR-20b |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
mmu-miR-703 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
MRUL |
Curated lncRNA |
gastric cancer |
|
| Doxorubicin (Adriamycin) |
MT1CP |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
PCGEM1 |
Curated lncRNA |
prostate cancer |
|
| Doxorubicin (Adriamycin) |
rno-mir-301a |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
rno-mir-93 |
Curated miRNA |
breast cancer |
|
| Doxorubicin (Adriamycin) |
SNHG10 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
uc002sts.4 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
uc003txt.3 |
Curated lncRNA |
osteosarcoma |
|
| Doxorubicin (Adriamycin) |
uc010lgv.1 |
Curated lncRNA |
osteosarcoma |
|
